Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.193
+0.003 (0.10%)
May 13, 2025, 4:00 PM - Market closed
Kiora Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | - | 16 | - | - | - | 0.01 | Upgrade
|
| Other Revenue | 0.02 | 0.02 | - | - | - | - | Upgrade
|
| Revenue | 0.02 | 16.02 | - | - | - | 0.01 | Upgrade
|
| Revenue Growth (YoY) | -99.88% | - | - | - | - | -99.55% | Upgrade
|
| Cost of Revenue | 0.38 | 0.38 | 0.41 | 3.45 | 5.35 | 3.27 | Upgrade
|
| Gross Profit | -0.36 | 15.64 | -0.41 | -3.45 | -5.35 | -3.26 | Upgrade
|
| Selling, General & Admin | 5.74 | 5.54 | 4.66 | 7.28 | 5.22 | 4.24 | Upgrade
|
| Research & Development | 3.59 | 4.52 | 3.62 | - | - | - | Upgrade
|
| Operating Expenses | 9.32 | 10.06 | 8.28 | 7.28 | 5.22 | 4.24 | Upgrade
|
| Operating Income | -9.68 | 5.58 | -8.69 | -10.73 | -10.57 | -7.51 | Upgrade
|
| Interest Expense | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0 | Upgrade
|
| Interest & Investment Income | 1.31 | 1.25 | 0.17 | 0.06 | 0 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0.03 | 0.03 | -1.44 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -8.4 | 6.84 | -8.5 | -12.12 | -10.58 | -7.49 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.1 | -0.41 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -4.04 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0 | -0.03 | 0 | - | 0.11 | Upgrade
|
| Asset Writedown | -0.1 | -0.1 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.65 | 0.94 | -1.99 | -1.58 | 0.75 | 0.94 | Upgrade
|
| Pretax Income | -9.86 | 5.66 | -12.42 | -13.7 | -13.96 | -6.85 | Upgrade
|
| Income Tax Expense | 2.19 | 2.07 | 0.09 | -0.11 | -0.19 | 0.01 | Upgrade
|
| Earnings From Continuing Operations | -12.05 | 3.59 | -12.51 | -13.58 | -13.77 | -6.86 | Upgrade
|
| Net Income | -12.05 | 3.59 | -12.51 | -13.58 | -13.77 | -6.86 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 0.53 | - | - | - | Upgrade
|
| Net Income to Common | -12.05 | 3.59 | -13.04 | -13.58 | -13.77 | -6.86 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 4 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 4 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 188.28% | 666.73% | 561.21% | 203.73% | 110.04% | - | Upgrade
|
| EPS (Basic) | -2.86 | 0.93 | -24.25 | -166.94 | -514.04 | -538.01 | Upgrade
|
| EPS (Diluted) | -2.87 | 0.87 | -24.25 | -166.94 | -514.04 | -538.01 | Upgrade
|
| Free Cash Flow | -7.78 | 8.55 | -9.56 | -10.43 | -10.74 | -7.34 | Upgrade
|
| Free Cash Flow Per Share | -1.85 | 2.07 | -17.76 | -128.16 | -400.88 | -575.29 | Upgrade
|
| Gross Margin | - | 97.63% | - | - | - | - | Upgrade
|
| Operating Margin | -48421.22% | 34.84% | - | - | - | -62238.67% | Upgrade
|
| Profit Margin | -60257.27% | 22.44% | - | - | - | -56901.65% | Upgrade
|
| Free Cash Flow Margin | -38880.97% | 53.39% | - | - | - | -60844.56% | Upgrade
|
| EBITDA | -9.67 | 5.6 | -8.64 | -10.69 | -10.53 | -7.47 | Upgrade
|
| EBITDA Margin | - | 34.96% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.02 | 0.05 | 0.04 | 0.05 | 0.03 | Upgrade
|
| EBIT | -9.68 | 5.58 | -8.69 | -10.73 | -10.57 | -7.51 | Upgrade
|
| EBIT Margin | - | 34.84% | - | - | - | - | Upgrade
|
| Effective Tax Rate | - | 36.49% | - | - | - | - | Upgrade
|
| Revenue as Reported | 0.02 | 16.02 | - | - | - | - | Upgrade
|
Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.